Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$326000.0.

  • CytomX Therapeutics' Change in Accured Expenses fell 11603.54% to -$326000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.1 million, marking a year-over-year decrease of 24298.11%. This contributed to the annual value of -$9.6 million for FY2024, which is 3674.19% down from last year.
  • As of Q3 2025, CytomX Therapeutics' Change in Accured Expenses stood at -$326000.0, which was down 11603.54% from -$1.1 million recorded in Q2 2025.
  • CytomX Therapeutics' Change in Accured Expenses' 5-year high stood at $8.1 million during Q4 2021, with a 5-year trough of -$7.4 million in Q1 2023.
  • For the 5-year period, CytomX Therapeutics' Change in Accured Expenses averaged around -$1.2 million, with its median value being -$1.4 million (2022).
  • Per our database at Business Quant, CytomX Therapeutics' Change in Accured Expenses skyrocketed by 56705.07% in 2021 and then crashed by 93211.92% in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Change in Accured Expenses stood at $8.1 million in 2021, then crashed by 147.94% to -$3.9 million in 2022, then soared by 136.63% to $1.4 million in 2023, then plummeted by 490.03% to -$5.6 million in 2024, then surged by 94.13% to -$326000.0 in 2025.
  • Its Change in Accured Expenses was -$326000.0 in Q3 2025, compared to -$1.1 million in Q2 2025 and -$2.1 million in Q1 2025.